Cite
HARVARD Citation
Yao, R. et al. (2019). Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China. Medicine. 98 (39), p. . [Online].